Search Results

Trevena, Inc. today reported its financial results for the first quarter ended March 31, 2024 and provided an overview of its recent operational highlights.

Trevena Inc. announced that it has entered into definitive agreements for the issuance and sale of 2,779,906 shares of common stock of Trevena and warrants to purchase up to an aggregate of 2,779,906 shares of common stock of Trevena, at a purchase price of $0.70 per share and associated warrant in a private placement, for expected gross proceeds to the Company of approximately $1.946 million.

Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced preclinical data from two separate research collaborations.

Trevena Inc. has been awarded a national group purchasing agreement for OLINVYK with Premier, Inc. Effective December 1, 2023, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for OLINVYK.

Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the fourth quarter ended December 31, 2023 and provided an overview of its recent operational highlights.

Trevena, Inc. announced that it has closed its previously announced offering for the issuance and sale of 2,779,906 shares of common stock of Trevena and warrants to purchase up to an aggregate of 2,779,906 shares of common stock of Trevena, at a purchase price of $0.70 per share and associated warrant in a private placement, for gross proceeds to the Company of approximately $1.946 million.

Trevena, Inc. announced that Mark Corrigan, M.D. has been appointed to the Company’s Board of Directors, effective July 18 2023.

Trevena, Inc. reported its financial results for the third quarter ended September 30, 2023 and provided an overview of its recent operational highlights.